charged multivesicular body protein 5Genealiases: C9orf83 · CGI-34 · HSPC177 · PNAS-2 · SNF7DC2 · Spike
Q-omics provides the consensus-scored CHMP5 profile across patient tissues and cancer cell-line models. CHMP5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHMP5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CHMP5 protein abundance shows 18,982 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where CHMP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHMP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHMP5 survival associations across molecular data types. CHMP5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHMP5 RNA expression–survival associations across cancer types. High CHMP5 expression shows unfavorable associations in ACC, UVM, HNSC and LIHC, but favorable associations in KIRC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHMP5 RNA expression.
This table summarizes CHMP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CHMP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHMP5 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, BRCA and CHOL. The HNSC box plot shows higher CHMP5 RNA expression in tumor versus normal tissue (log2 FC = +0.747, t-test p < 0.001).
This table shows molecular features associated with CHMP5 in patient tissues and cancer cell lines. In patient samples, CHMP5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHMP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
